CADTH recommends reimbursement for BioCryst’s Orladeyo (berotralstat) for the routine prevention of attacks in hereditary angioedema patients in Canada

8 March 2023 - BioCryst Pharmaceuticals today announced that the CADTH Canadian Drug Expert Committee has issued a positive recommendation ...

Read more →

Health minister disputes claim he sided with big pharma, interfered with drug price consultations

1 March 2023 - Review board 'will never be subjected to political interference,' Duclos said. ...

Read more →

The drug prices review board was once a solution. It’s now a problem.

1 March 2023 - Anti-drug company activists are repeating ill-informed myths about controlling drug prices in Canada. ...

Read more →

Member of Canada’s drug pricing regulator quits over ‘lack of support’ for medicine cost reforms

23 February 2023 - A member of the Patented Medicine Prices Review Board, Canada’s drug pricing regulator, has resigned over ...

Read more →

Valeo Pharma obtains public reimbursement for Onstryv in Quebec

7 February 2023 - Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson’s patients in Quebec. ...

Read more →

Medexus secures public reimbursement for Cuvposa in Quebec

1 February 2023 - Medexus Pharmaceuticals wishes to inform investors that the company has reached an agreement with the provincial government ...

Read more →

Radicava (edarvarone) oral suspension receives positive recommendation from CADTH for the treatment of patients with ALS

18 January 2023 - Mitsubishi Tanabe Pharma Canada is pleased to announce a positive recommendation from the CADTH Canadian Drug Expert ...

Read more →

Innovative Medicines Canada proposes framework for innovative agreements for drug reimbursement

16 January 2023 - Pharmaceutical manufacturers in Canada often enter into product listing agreements, particularly with public payers, to facilitate their ...

Read more →

Ontario expanding safe use of biosimilars

20 December 2022 - Transitioning to biosimilars will allow province to invest in and improve access to medicines. ...

Read more →

Radicava (edaravone) oral suspension receives positive recommendation from INESSS for the treatment of patients with ALS

19 December 2022 - Mitsubishi Tanabe Pharma Canada is pleased to announce a positive recommendation from the Institut national d'excellence en ...

Read more →

AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan

1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status ...

Read more →

Livtencity (maribavir) receives positive CADTH recommendation for adults with post-transplant cytomegalovirus infection

1 December 2022 - The conditions for the positive recommendation is supported by the findings of the Phase 3 SOLSTICE ...

Read more →

Implementation of the Patented Medicine Prices Review Board's proposed Guidelines will harm Canadian patients

10 November 2022 - Innovative Medicines Canada is calling on Health Canada to direct the Patented Medicine Prices Review Board (PMPRB) ...

Read more →

Vabysmo (faricimab) receives positive CADTH recommendation for the treatment of diabetic macular oedema in adults

3 November 2022 - This CADTH recommendation is the latest step towards public access to Vabysmo (faricimab) for the estimated 60,000 ...

Read more →

New PMPRB guidelines proposed for assessing prices of patented medicines sold in Canada

4 November 2022 - Controversial amendments to the Patented Medicines Regulations changing the basket of comparator countries considered by the ...

Read more →